The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Salix Pharmaceuticals Ltd.

  • SLXP
  • NASDAQ
  • Consumer Products
  • Latest 109.388
  • Currency US$
  • Change 0.319
  • Percent Change 0.292 %
  • Volume 11,288
  • Wed Apr 23, 2014 09:33 AM EDT NASDAQ data delayed 15 minutes.
  • Open 109.28
  • Previous Close 109.07
  • High 110.01
  • Low 109.24
  • Bidx1 109.24
  • Askx1 109.38
  • 52-week High02/28 120.00
  • 52-week Low04/22 48.46
  • Beta 1.048
  • Market Cap 6,880.54M
  • EPS 2.02
  • P/E 54.153
  • Forward P/E 18.21
  • PEG 1.02
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $933,830,000
  • Earnings $143,030,000
  • Return on Equity 20.15%

Cash Flow

  • Cash Flow --
  • Cash $1,157,850,000
  • Current Ratio 5.46

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,941,390,000
  • Liabilities $2,200,520,000
  • Liabilities-to-Equity Ratio 2.97

Price Ratios

  • Price to Sales 7.37
  • Price to Book 9.29
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 27 $0.64 May 8 $0.35
Surprises Feb 27 45.31% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 23, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialty pharmaceutical company focussed on the needs of physicians specializing in gastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company's strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease.

Related Securities
Symbol Type Latest % Chg

Officers

  • Thomas W. D'Alonzo Chairman of the Board
  • Carolyn J. Logan President; Chief Executive Of
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

8510 COLONNADE CENTER DRIVE
RALEIGH, NC
27615

Phone: (919)-862-1000
Fax: (919)-8621095

investor.relations@salix.com
www.salix.com

Ideas & Discussion

Live Discussion of SLXP on StockTwits